We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current PTX market cap is 31.41M. The company's latest EPS is AUD -0.0102 and P/E is -3.92.
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 1.08M | 1.24M | 1.89M | 2.43M | 3.71M |
| Operating Income | -3.42M | -4.19M | -5.21M | -7.46M | -8.9M |
| Net Income | -3.32M | -4.15M | -5.12M | -7.01M | -8.24M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 12.07M | 20.97M | 17.62M | 28.11M | 20.39M |
| Total Liabilities | 884k | 540k | 856k | 2.03M | 2.33M |
| Total Equity | 11.19M | 20.43M | 16.76M | 26.08M | 18.07M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -2.32M | -3.97M | -4.31M | -6.19M | -7.4M |
| Investing | N/A | -2k | -4k | N/A | 12M |
| Financing | N/A | 12.75M | 428k | -172k | 18k |
| Market Cap | 31.41M |
| Price to Earnings Ratio | -3.92 |
| Price to Sales Ratio | 8.7 |
| Price to Cash Ratio | 3.08 |
| Price to Book Ratio | 1.78 |
| Dividend Yield | - |
| Shares Outstanding | 805.32M |
| Average Volume (1 week) | 341.38k |
| Average Volume (1 Month) | 686.56k |
| 52 Week Change | -35.00% |
| 52 Week High | 0.105 |
| 52 Week Low | 0.037 |
| Spread (Intraday) | 0 (2.5%) |
| Company Name | Prescient Therapeutics Limited |
| Address |
level 4 melbourne, victoria 3205 |
| Website | https://www.ptxtherapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
